MuScreen™ – the First In Vivo IO Syngeneic Screening Platform

Immunotherapeutics can be difficult to evaluate preclinically - in vitro cell-based screens usually used to quickly identify responsive cells and assess PD effects often fail in immuno-oncology, due to IO agents targeting the complex host immune system.